Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Novel multimodal approach to atrial fibrillation risk assessment and identification of targets for prevention by interdisciplinary exploitation of omics, advanced electrocardiography, and imaging

Objectif

There is a growing need for novel risk schemes in atrial fibrillation (AF) to permit prevention, contribute to a better understanding of the pathophysiology, and discover targets for individualized treatment.
Primary prevention efforts are scant despite the imminent AF epidemic. In international cohorts I have developed and validated the first risk prediction algorithm. However, it explains only 60% of the attributable risk and efforts at improving discrimination are urgently required.
Therefore, my overall goal is to develop an enhanced risk prediction algorithm based on cutting-edge technology. The specific focus will be on parameters representative of early stages of the disease process and intermediate phenotypes such as atrial electrical and structural remodelling, chronic subclinical inflammation, oxidative stress, and autonomous tone in manifest and incident AF. Subclinical, potentially reversible changes are ideally suited to provide independent information complementary to known risk markers.
My ambitious concept is to choose a multimodal approach in an interdisciplinary team to systematically assess:
1) Blood and tissue omics (genomics, expression, proteomics, metabolomics),
2) Advanced electrocardiography,
3) Imaging (echocardiography, cardiac MRI), and
4) Gender applying innovative tools and analyses strategies aimed at a systems biology integration of the accumulated information.
I have collected comprehensive biological and epidemiologic information on distinct AF phenotypes in unique prospective population (N>60,000) and clinical cohorts (N>1,000). We are not aware of other groups with access to such a well-established prospective AF biobank.
Informed by omics, electrocardiography and imaging we will provide pathophysiological insights into the disease process, highlight targets for intervention, and develop a contemporary risk scheme. Our results will lay the ground for rapid translation into clinical practice with significant public health impact.

Régime de financement

ERC-COG - Consolidator Grant

Institution d’accueil

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Contribution nette de l'UE
€ 1 999 305,00
Adresse
Martinistrasse 52
20251 Hamburg
Allemagne

Voir sur la carte

Région
Hamburg Hamburg Hamburg
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 1 999 305,00

Bénéficiaires (1)